Pliant Therapeutics' GAAP loss for 3 months of 2022 was $28.1 million, up 22.9% from $22.856 million in the prior year. Revenue decreased 42.5% to $1,249 million from $2,174 million a year earlier.
Pliant Therapeutics' GAAP loss for 3 months of 2022 was $28.1 million, up 22.9% from $22.856 million in the prior year. Revenue decreased 42.5% to $1,249 million from $2,174 million a year earlier. 
ir.pliantrx.com
English (US) 